Conduct research and development of new pharmaceutical products across various therapeutic areas. Now — the numbers.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $6.2B would still be left in the vault — a solid cushion for hard times.
The market pays 23.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 35% — still a thick cushion, though costs have been eating into it lately.
There is $6.4B in the vault; even if every debt were paid off, $6.2B would remain.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
Against everything we grade, CHGCY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: CHGCY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.